2021年8月6号，新加坡卫生部发布消息称所有接种了WHO批准紧急使用新冠疫苗第二针超过14天的人皆被视为完全接种人群。可对这批人群放宽活动限制。那哪些国内的疫苗符合这一条件呢？
SINGAPORE: People who opt for Sinovac and other COVID-19 vaccines under the World Health Organization's (WHO) emergency use list will be considered as fully vaccinated from next Tuesday (Aug 10), the Ministry of Health (MOH) said on Friday.
This means that those who have taken both doses of the Sinovac, Sinopharm and AstraZeneca vaccines – and two weeks have passed after their second jab – will be eligible for vaccination-differentiated safe management measures such as dining-in at F&B outlets in bigger groups and travel concessions.
国药（中国医药集团）有两款新冠疫苗在中国使用，分别是北京生物和武汉生物新冠疫苗。2021年5月7号国药的北京生物新冠疫苗获得WHO紧急使用批准。随后，6月1号，科兴生产的Sinovac也获WHO批准。截止至7月15号，国药的武汉生物（代号Sinopharm/WIBP）新冠疫苗尚未通过WHO批准。获得WHO批准的北京生物新冠疫苗的英文名称是：Sinopharm COVID-19 vaccines (International non-proprietary name: Covilo; BIBP-CorV)，这里的BIBP是北京生物的代号（ Beijing Bio-Institute of Biological Products Co-Ltd ）。
所以，目前符合这一条件的有两款疫苗：国药旗下北京生物开发的Sinopharm/BIBP，以及科兴生物开发的Sinovac
WHO关于新冠疫苗评估的官方网页：https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
WHO评估的新冠疫苗最新动态（2021年8月7号查询）附图如下：
